ArriVent BioPharma, Inc. Common Stock (AVBP) Earnings History
Net Loss5 years of earnings data (2021–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
ArriVent BioPharma, Inc. Common Stock (AVBP) Earnings Overview
As of June 28, 2026, ArriVent BioPharma, Inc. Common Stock (AVBP) reported trailing twelve-month net income of -$145M, reflecting -68.8% year-over-year growth. The company earned $-3.22 per diluted share over the past four quarters.
Looking at the long-term picture, AVBP's historical earnings data spans multiple years. The company achieved its highest annual net income of -$37M in fiscal 2022.
ArriVent BioPharma, Inc. Common Stock is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RCUS (-$369M net income, -142.9% margin), TPVG (-$12M net income, 50.6% margin), KYMR (-$315M net income, -794.4% margin), AVBP has comparable earnings metrics. Compare AVBP vs RCUS →
AVBP Earnings vs Peers
Earnings metrics vs comparable public companies
AVBP Historical Earnings Data (2021–2025)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$166M | -106.6% | -$178M | $-4.32 | - | - |
| 2024 | -$80M | -16.1% | -$94M | $-2.56 | - | - |
| 2023 | -$69M | -87.9% | -$75M | $-2.17 | - | - |
| 2022 | -$37M | +28.5% | -$37M | $-1.10 | - | - |
| 2021 | -$52M | - | -$9M | $-40.44 | - | - |
Download Data
Export AVBP earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AVBP — Frequently Asked Questions
Quick answers to the most common questions about buying AVBP stock.
What is AVBP earnings per share (EPS)?
AVBP trailing twelve-month (TTM) diluted EPS is $-3.22, reflecting -68.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2021 to 2025 is available in the table on this page.
What is ArriVent BioPharma, Inc. Common Stock's net income?
ArriVent BioPharma, Inc. Common Stock (AVBP) trailing twelve-month net income is $-145M as of 2025. Earnings declined -68.8% year-over-year.
Is AVBP profitable?
AVBP is not currently profitable on a TTM basis, reporting a net loss of $-145M. Net margin is N/A. Investors should monitor for a return to profitability.
What is AVBP's earnings growth rate?
AVBP compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2021 to 2025.
What are AVBP's profit margins?
ArriVent BioPharma, Inc. Common Stock net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -58.9%.
Is AVBP growing earnings?
AVBP earnings are declining — EPS fell -68.8% year-over-year. TTM net income dropped to $-145M. This contrasts with the 5-year CAGR of N/A.
What was AVBP's best earnings year?
ArriVent BioPharma, Inc. Common Stock's highest annual net income on record is $-37M, achieved in fiscal year 2022. Earnings history on this page spans 2021 to 2025 and includes all annual and quarterly figures.
What were AVBP's earnings last quarter?
AVBP's most recent reported quarter was Q1 2026. Net income was $-43M with diluted EPS of $-0.96. For a full breakdown of all quarters, see the quarterly earnings table on this page.